Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study

Yuki Katayama, MD, PhD; Tadaaki Yamada, MD, PhD; Kenji Morimoto, MD, PhD; Hiroyuki Fujii, MD; Satomi Morita, MD, PhD; Keiko Tanimura, MD, PhD; Takayuki Takeda, MD, PhD; Asuka Okada, MD, PhD; Shinsuke Shiotsu, MD, PhD; Yusuke Chihara, MD, PhD; Osamu Hiranuma, MD; Takahiro Yamada, MD, PhD; Takahiro Ota, MD, PhD; Taishi Harada, MD; Isao Hasegawa, MD, PhD; Masahiro Iwasaku, MD, PhD; Shinsaku Tokuda, MD, PhD; Noriyuki Tanaka, MD, PhD; Aya Miyagawa-Hayashino, MD, PhD; Koichi Takayama, MD, PhD

JTO Clinical and Research Reports (Mar 2024)

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study

Yuki Katayama, MD, PhD,
Tadaaki Yamada, MD, PhD,
Kenji Morimoto, MD, PhD,
Hiroyuki Fujii, MD,
Satomi Morita, MD, PhD,
Keiko Tanimura, MD, PhD,
Takayuki Takeda, MD, PhD,
Asuka Okada, MD, PhD,
Shinsuke Shiotsu, MD, PhD,
Yusuke Chihara, MD, PhD,
Osamu Hiranuma, MD,
Takahiro Yamada, MD, PhD,
Takahiro Ota, MD, PhD,
Taishi Harada, MD,
Isao Hasegawa, MD, PhD,
Masahiro Iwasaku, MD, PhD,
Shinsaku Tokuda, MD, PhD,
Noriyuki Tanaka, MD, PhD,
Aya Miyagawa-Hayashino, MD, PhD,
Koichi Takayama, MD, PhD

Affiliations

Yuki Katayama, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Tadaaki Yamada, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Corresponding author. Address for correspondence: Tadaaki Yamada, MD, PhD, Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
Kenji Morimoto, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Hiroyuki Fujii, MD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Satomi Morita, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Keiko Tanimura, MD, PhD: Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
Takayuki Takeda, MD, PhD: Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
Asuka Okada, MD, PhD: Department of Respiratory Medicine, Saiseikai Suita Hospital, Osaka, Japan
Shinsuke Shiotsu, MD, PhD: Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
Yusuke Chihara, MD, PhD: Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan
Osamu Hiranuma, MD: Department of Respiratory Medicine, Otsu City Hospital, Shiga, Japan
Takahiro Yamada, MD, PhD: Department of Respiratory Medicine, Matsushita Memorial Hospital, Osaka, Japan
Takahiro Ota, MD, PhD: Department of Respiratory Medicine, Kyoto city Hospital, Kyoto, Japan
Taishi Harada, MD: Department of Medical Oncology, Fukuchiyama City Hospital, Kyoto, Japan
Isao Hasegawa, MD, PhD: Department of Respiratory Medicine, Saiseikai Shigaken Hospital, Shiga, Japan
Masahiro Iwasaku, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Shinsaku Tokuda, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Noriyuki Tanaka, MD, PhD: Department of Pathology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Aya Miyagawa-Hayashino, MD, PhD: Department of Pathology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Koichi Takayama, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Journal volume & issue: Vol. 5, no. 3
p. 100644

Abstract

Read online

Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear. Methods: In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients. Results: The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival. Conclusions: In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords